Metabolomics Market Analysis | 2022-2028

“The Metabolomics Market was estimated at US$ 2.3 billion in 2021 and is expected to grow at a CAGR of 14.86% during 2022-2028 to reach US$ 6.18 billion in 2028”.

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Metabolomics is the comprehensive study of metabolites, the small molecules involved in metabolic processes within biological systems, such as cells, tissues, or organisms. This field focuses on identifying, quantifying, and analyzing these metabolites to gain insights into biochemical activities and changes associated with diseases, environmental influences, or genetic modifications.

By using advanced analytical techniques like mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy, metabolomics helps to map out metabolic pathways, understand cellular responses, and discover potential biomarkers for disease diagnosis and treatment. It plays a crucial role in personalized medicine, drug development, and understanding complex biological processes.

Market Drivers

Due to rising government and private investment in research and development, as well as the rise in metabolic applications in personalized medicine, the global metabolomics market is anticipated to experience a profitable growth rate throughout the forecast period. In terms of size, the market is dominated by instruments, largely because metabolomics equipment is employed extensively when carrying out the various parts of the experimental protocol.

Metabolomics bioinformatics tools and services are anticipated to increase more quickly in the future because they make it easier to analyze and interpret biological data that is already publicly available. Numerous fields, such as biomarker identification, drug development, toxicological testing, nutrigenomics, functional genomics, personalized medicine, and others, have found extensive use for metabolomics.

The market's greater contribution to the identification of new biomarkers is also driven by considerable oncological research with a preference for the study of these markers and their use in the treatment of cancer. Key firms have a tremendous opportunity to explore the unexplored market in developing nations thanks to the metabolomics sector. The vast array of upcoming research in the area of developing biomarkers also offers enormous prospects for the expansion of the global metabolomics market.

Several investments/guidelines in the market have been directed in recent years, which would boost the overall market. Some of them are:

• The rise in government and private organization financing for technical research, as well as the expansion of key players' partnerships and collaborations for the improvement of their product portfolio, are only a few of the reasons influencing the growth of the metabolomics sector. The leading companies have significantly increased their R&D spending in order to create cutting-edge metabolomics platforms, which is anticipated to propel the market's expansion throughout the course of the projected year. The development of personalized medicine also contributes to the market's expansion. The high cost of instruments and equipment, data reprocessing and validation, and other considerations are, however, impeding the market's expansion. An issue for the market is finding skilled labor to comprehend the complexity of biological samples.

Recent Developments

The metabolomics market is highly competitive. The market players are highly focused on mergers, expansions, and product approvals, to sustain in this market. Below are a few key developments:

• In September 2022, Merck, a renowned science and technology company, erected a viral clearance (VC) laboratory as part of the first phase of building of its new € 29 million China Biologics Testing Center. It is Merck's first facility of its kind in China and is 5,000 square meters in size. The VC laboratory will let enterprises conduct viral clearance investigations domestically, from pre-clinical research through commercialization, to meet China's double-digit demand for VC testing services. The VC laboratory will employ roughly 120 people by 2023.
• In August 2022, Charles River Laboratories International, Inc. announced that five new Charles River Accelerator and Development Lab (CRADL) sites would be opening in Washington and California. CRADL provides flexible, turnkey vivarium leasing space backed by Charles River's technical and veterinary support experience in significant biohubs. As a result of the recent acquisition of Explora Biolabs, the firm is constructing its first facility in Seattle and adding two more sites in San Diego to better serve the neighborhoods of Sorrento Valley and Torrey Pines. Additionally, CRADL launched a new location in Thousand Oaks in addition to expanding its South San Francisco operations.
• In April 2022, Charles River Laboratories International, Inc. acquired Explora BioLabs Holdings, Inc., a top provider of contract vivarium research services.
• In March 2022, BD, a preeminent worldwide medical technology company, unveiled the BD Rhapsody TCR/BCR Multiomic Assay, a cutting-edge package of reagents that enables researchers to more quickly and fully analyze crucial immune system cells. This test provides a tool to advance the study of infectious diseases, autoimmune diseases, and immuno-oncology.
• In January 2021, North Carolina-based Phitonex was acquired by Thermo Fisher Scientific. A spectrum dye platform for high-resolution biological applications has been created by Phitonex. The Phiton platform from Phitonex aims to speed up the advancement of cell therapy, immunology, and immuno-oncology. The platform provides a structure for maintaining a wider range of fluorescent dyes in predetermined ways, allowing researchers to get more comprehensive data from cell samples. Furthermore, it permits researchers to quickly create a range of dye labels that can be used to distinguish more proteins and cell types in a single experiment.
• In March 2019, Lonza unveiled CellBio Services, a wide range of distinctive, specialized solutions made to suit specific, unique research application demands. A wide range of services, including medium preparation, cell separation, cell characterization, transfection services, cell-line expansion and banking, and three-dimensional (3D) cell culture, are available to researchers working with pharmaceutical and contract manufacturing organizations.

Segments Analysis

By Product and Service Type

The market is further segmented into metabolomics instruments, and metabolomics bioinformatics tools and services. The instruments segment is further divided into separation tools and detection tools. The separation tools are segmented into high-performance liquid chromatography (HPLC), gas chromatography (GC), ultra-performance liquid chromatography (UPLC), and capillary electrophoresis (CE). The detection tools are segmented into mass spectrometry, nuclear magnetic resonance spectroscopy (NMR), and surface-based mass analysis.

By Clinical Indication Type

The market has been divided into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. The metabolomics market is mostly driven by cancer among the various clinical indications. The increased frequency of cancer worldwide and the expansion of oncological research efforts are the main causes of this.

The World Health Organization (WHO) reports that cancer is the second biggest cause of death worldwide, accounting for 8.8 million fatalities. Cardiovascular problems, neurological conditions, inborn metabolic abnormalities, and other clinical indications for metabolomics are also included.

Regional Analysis

"North America is the largest market for metabolomics, while the Asia-Pacific region is expected to experience the fastest growth rate during the forecast period."

The metabolomics market is broken down geographically into geographies, namely North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Due to factors including the presence of several financing sources from both public and private agencies, the accessibility of technologically cutting-edge products, and the dominance of some of the important firms in the region, North America is the largest market for metabolomics goods and services.

The Asia-Pacific region is anticipated to witness the quickest growth rate in the metabolomics market during the forecast period. Its expansion is primarily driven by rising healthcare and R&D spending, an increase in the use of technology in clinical settings, and a growing interest among large businesses in exploring unexplored markets.

Key Players

The following are the key players in the Metabolomics Market (arranged alphabetically)

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Bruker Corporation
• Danaher Corporation
• Human Metabolome Technologies Inc.
• Metabolon, Inc.
• Shimadzu Corporation
• Waters Corporation

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.